BioCentury | Aug 2, 2010
Clinical News

Ashkenazi Jews Genetic Disease Panel regulatory update

...Services Inc. , Houston, Texas Interleukin Genetics Inc. (NYSE-A:ILI), Waltham, Mass. DNATraits , Houston, Texas CyGene Laboratories Inc....
BioCentury | Aug 10, 2009
Company News

CyGene sales and marketing update

...cardiovascular disease, Type II diabetes and obesity, glaucoma and macular degeneration, osteoporosis and autoimmune diseases. CyGene Laboratories Inc....
BioCentury | Jul 28, 2008
Company News

CyGene sales and marketing update

...stroke, cardiovascular or kidney disease. The test has CLIA certification and is priced at $499. CyGene Laboratories Inc....
BioCentury | Jan 8, 2007
Strategy

Thinking globally

Thinking globally Company Notes Bionomics (ASX:BNO) Acquired French company Neurofit in 2005, giving it preclinical CNS development capabilities Biota (ASX:BTA) Acquired U.S. antiviral company NuMax in 2001 Bone Medical (ASX:BNE) Osteoporosis and arthritis company with...
BioCentury | Sep 18, 2006
Company News

CyGenics gene/cell therapy news

CYN said it is seeking to out-license its stem cell expansion and T cell production technologies to focus on its tissue and cord blood banking business. The company said it will continue to expand these...
BioCentury | Sep 11, 2006
Company News

CyGenics, DNAPro Sdn Bhd deal

Cord blood banking and cell therapy company CYN sold its Cell Sciences Pte Ltd. subsidiary, which distributes medical and research products, for a 20% stake in DNAPro. CYN said the equity stake is valued at...
BioCentury | Jun 12, 2006
Company News

CyGenics, PharmaCell deal

CYN purchased a 20% stake in PharmaCell for an undisclosed amount of cash. In exchange, CYN said it will have access to PharmaCell's cGMP manufacturing facility, where it will manufacture cell therapy products. CYN, which...
BioCentury | Feb 20, 2006
Company News

CyGenics board of directors update

CyGenics Ltd. (ASX:CYN), Melbourne, Australia Business: Gene/Cell therapy Appointed: Alberto Bautista, an industry consultant WIR Staff...
BioCentury | Dec 19, 2005
Company News

CyGenics management update

CyGenics Ltd. (ASX:CYN), Sydney, Australia Business: Gene/Cell therapy Hired: Mark Kirkland as CSO, formerly CEO of BioCell Pty Ltd. WIR Staff...
BioCentury | Dec 12, 2005
Clinical News

CyGenics preclinical data

In mice, thymus-derived stem cells cultured on skin cells did not produce graft-versus-host disease (GVHD). CYN's ex vivo T cell production technology generates T cells from autologous skin cells and bone marrow stem cells for...
Items per page:
1 - 10 of 14
BioCentury | Aug 2, 2010
Clinical News

Ashkenazi Jews Genetic Disease Panel regulatory update

...Services Inc. , Houston, Texas Interleukin Genetics Inc. (NYSE-A:ILI), Waltham, Mass. DNATraits , Houston, Texas CyGene Laboratories Inc....
BioCentury | Aug 10, 2009
Company News

CyGene sales and marketing update

...cardiovascular disease, Type II diabetes and obesity, glaucoma and macular degeneration, osteoporosis and autoimmune diseases. CyGene Laboratories Inc....
BioCentury | Jul 28, 2008
Company News

CyGene sales and marketing update

...stroke, cardiovascular or kidney disease. The test has CLIA certification and is priced at $499. CyGene Laboratories Inc....
BioCentury | Jan 8, 2007
Strategy

Thinking globally

Thinking globally Company Notes Bionomics (ASX:BNO) Acquired French company Neurofit in 2005, giving it preclinical CNS development capabilities Biota (ASX:BTA) Acquired U.S. antiviral company NuMax in 2001 Bone Medical (ASX:BNE) Osteoporosis and arthritis company with...
BioCentury | Sep 18, 2006
Company News

CyGenics gene/cell therapy news

CYN said it is seeking to out-license its stem cell expansion and T cell production technologies to focus on its tissue and cord blood banking business. The company said it will continue to expand these...
BioCentury | Sep 11, 2006
Company News

CyGenics, DNAPro Sdn Bhd deal

Cord blood banking and cell therapy company CYN sold its Cell Sciences Pte Ltd. subsidiary, which distributes medical and research products, for a 20% stake in DNAPro. CYN said the equity stake is valued at...
BioCentury | Jun 12, 2006
Company News

CyGenics, PharmaCell deal

CYN purchased a 20% stake in PharmaCell for an undisclosed amount of cash. In exchange, CYN said it will have access to PharmaCell's cGMP manufacturing facility, where it will manufacture cell therapy products. CYN, which...
BioCentury | Feb 20, 2006
Company News

CyGenics board of directors update

CyGenics Ltd. (ASX:CYN), Melbourne, Australia Business: Gene/Cell therapy Appointed: Alberto Bautista, an industry consultant WIR Staff...
BioCentury | Dec 19, 2005
Company News

CyGenics management update

CyGenics Ltd. (ASX:CYN), Sydney, Australia Business: Gene/Cell therapy Hired: Mark Kirkland as CSO, formerly CEO of BioCell Pty Ltd. WIR Staff...
BioCentury | Dec 12, 2005
Clinical News

CyGenics preclinical data

In mice, thymus-derived stem cells cultured on skin cells did not produce graft-versus-host disease (GVHD). CYN's ex vivo T cell production technology generates T cells from autologous skin cells and bone marrow stem cells for...
Items per page:
1 - 10 of 14